Lymphoblastic Leukemia Clinical Trials

364 recruitingLast updated: June 18, 2026

There are 364 actively recruiting lymphoblastic leukemia clinical trials across 58 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Duarte, California, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Lymphoblastic Leukemia Trials at a Glance

364 actively recruiting trials for lymphoblastic leukemia are listed on ClinicalTrialsFinder across 6 cities in 58 countries. The largest study group is Phase 2 with 162 trials, with the heaviest enrollment activity in Houston, Duarte, and Seattle. Lead sponsors running lymphoblastic leukemia studies include Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University, and City of Hope Medical Center.

Browse lymphoblastic leukemia trials by phase

Treatments under study

About Lymphoblastic Leukemia Clinical Trials

Looking for clinical trials for Lymphoblastic Leukemia? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoblastic Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 364 trials

Recruiting
Phase 2

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaB-ALL
National Cancer Institute (NCI)20 enrolled1 locationNCT07328503
Recruiting
Not Applicable

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Acute Lymphoblastic LeukemiaB-ALL
National Cancer Institute (NCI)60 enrolled8 locationsNCT05621291
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)222 enrolled152 locationsNCT06124157
Recruiting
Early Phase 1

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University20 enrolled2 locationsNCT07074496
Recruiting
Not Applicable

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

InsomniaAcute Lymphoblastic Leukemia ALLSurvivor of Childhood Cancer
St. Jude Children's Research Hospital40 enrolled1 locationNCT07191119
Recruiting
Phase 1

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

LymphomaT-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center18 enrolled1 locationNCT07513129
Recruiting
Phase 1

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

SarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaNeurofibroma, Plexiform+1 more
National Cancer Institute (NCI)54 enrolled1 locationNCT02390752
Recruiting
Not Applicable

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia
University of Chicago38 enrolled1 locationNCT06446661
Recruiting
Phase 1Phase 2

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Phase 2

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recurrent B Acute Lymphoblastic LeukemiaDown Syndrome
National Cancer Institute (NCI)461 enrolled225 locationsNCT04546399
Recruiting
Phase 1Phase 2

Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

B-cell Acute Lymphoblastic Leukemia
Liping Dou20 enrolled1 locationNCT07575919
Recruiting
Phase 3

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center130 enrolled5 locationsNCT07223021
Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)153 enrolled113 locationsNCT06317662
Recruiting
Phase 3

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 2

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Acute Lymphoblastic Leukemia
Pfizer100 enrolled74 locationsNCT05748171
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 1

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Lymphoblastic LymphomaAcute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc24 enrolled4 locationsNCT07586618
Recruiting
Phase 1

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent B Acute Lymphoblastic Leukemia+1 more
University of Michigan Rogel Cancer Center12 enrolled1 locationNCT07532525